CT, RECIST, and malignant pleural mesothelioma

Anna Nowak

doi:10.1016/j.lungcan.2005.03.030

CT, RECIST, and malignant pleural mesothelioma

Anna Nowak

Graduate Research School

Research output: Contribution to journal › Article › peer-review

35 Citations (Scopus)

Abstract

The unique growth pattern of malignant pleural. mesothelioma (MPM) presents challenges for clinical investigators assessing tumour response to treatment. Assessment of response is an important surrogate for patient benefit, particularly in phase II clinical trials. Neither the previous WHO criteria nor the more recent RECIST criteria are well suited to tumour measurement in this disease. This paper discusses uni-dimensional measurement of tumour response in pleural mesothelioma, and the development and validation of the modified RECIST criteria for MPM, which attempt to overcome some of the shortcomings of the RECIST criteria in this setting. (c) 2005 Elsevier Ireland Ltd. All rights reserved.

Original language	English
Pages (from-to)	online - approx 5-10pp
Journal	Lung Cancer
Volume	49S1
DOIs	https://doi.org/10.1016/j.lungcan.2005.03.030
Publication status	Published - 2005

Access to Document

10.1016/j.lungcan.2005.03.030

Cite this

@article{47c9059da5754397be8d2045223726f9,

title = "CT, RECIST, and malignant pleural mesothelioma",

abstract = "The unique growth pattern of malignant pleural. mesothelioma (MPM) presents challenges for clinical investigators assessing tumour response to treatment. Assessment of response is an important surrogate for patient benefit, particularly in phase II clinical trials. Neither the previous WHO criteria nor the more recent RECIST criteria are well suited to tumour measurement in this disease. This paper discusses uni-dimensional measurement of tumour response in pleural mesothelioma, and the development and validation of the modified RECIST criteria for MPM, which attempt to overcome some of the shortcomings of the RECIST criteria in this setting. (c) 2005 Elsevier Ireland Ltd. All rights reserved.",

author = "Anna Nowak",

year = "2005",

doi = "10.1016/j.lungcan.2005.03.030",

language = "English",

volume = "49S1",

pages = "online -- approx 5--10pp",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier",

}

TY - JOUR

T1 - CT, RECIST, and malignant pleural mesothelioma

AU - Nowak, Anna

PY - 2005

Y1 - 2005

N2 - The unique growth pattern of malignant pleural. mesothelioma (MPM) presents challenges for clinical investigators assessing tumour response to treatment. Assessment of response is an important surrogate for patient benefit, particularly in phase II clinical trials. Neither the previous WHO criteria nor the more recent RECIST criteria are well suited to tumour measurement in this disease. This paper discusses uni-dimensional measurement of tumour response in pleural mesothelioma, and the development and validation of the modified RECIST criteria for MPM, which attempt to overcome some of the shortcomings of the RECIST criteria in this setting. (c) 2005 Elsevier Ireland Ltd. All rights reserved.

AB - The unique growth pattern of malignant pleural. mesothelioma (MPM) presents challenges for clinical investigators assessing tumour response to treatment. Assessment of response is an important surrogate for patient benefit, particularly in phase II clinical trials. Neither the previous WHO criteria nor the more recent RECIST criteria are well suited to tumour measurement in this disease. This paper discusses uni-dimensional measurement of tumour response in pleural mesothelioma, and the development and validation of the modified RECIST criteria for MPM, which attempt to overcome some of the shortcomings of the RECIST criteria in this setting. (c) 2005 Elsevier Ireland Ltd. All rights reserved.

U2 - 10.1016/j.lungcan.2005.03.030

DO - 10.1016/j.lungcan.2005.03.030

M3 - Article

C2 - 15950799

VL - 49S1

SP - online - approx 5-10pp

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

ER -

CT, RECIST, and malignant pleural mesothelioma

Abstract

Access to Document

Fingerprint

Cite this